These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 31017747)

  • 1. Transformation of lung adenocarcinoma to small cell lung carcinoma in the setting of tyrosine kinase inhibitor therapy: Cytological approach of a clinically challenging phenomenon.
    El Hussein S; Khader SN
    Diagn Cytopathol; 2019 Aug; 47(8):845-850. PubMed ID: 31017747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcome of patients with lung adenocarcinoma with transformation to small-cell lung cancer following tyrosine kinase inhibitors treatment: A systematic review and pooled analysis.
    Roca E; Gurizzan C; Amoroso V; Vermi W; Ferrari V; Berruti A
    Cancer Treat Rev; 2017 Sep; 59():117-122. PubMed ID: 28806542
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes.
    Offin M; Chan JM; Tenet M; Rizvi HA; Shen R; Riely GJ; Rekhtman N; Daneshbod Y; Quintanal-Villalonga A; Penson A; Hellmann MD; Arcila ME; Ladanyi M; Pe'er D; Kris MG; Rudin CM; Yu HA
    J Thorac Oncol; 2019 Oct; 14(10):1784-1793. PubMed ID: 31228622
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Small Cell Lung Cancer Derived from Adenocarcinoma with Mutant Epidermal Growth Factor Receptor Provides a Signature of Transcriptional Alteration in Tumor Cells.
    Tenjin Y; Nakamura K; Ishizuka S; Saruwatari K; Sato R; Tomita Y; Saeki S; Ichiyasu H; Fujii K; Ito T; Sakagami T
    Intern Med; 2019 Nov; 58(22):3261-3265. PubMed ID: 31292388
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Squamous cell carcinoma transformation of lung adenocarcinoma after tyrosine kinase inhibitor therapy: Cytological approach.
    Grosse A; Grosse C
    Cytopathology; 2020 May; 31(3):232-235. PubMed ID: 32072673
    [No Abstract]   [Full Text] [Related]  

  • 6. Transformation to small-cell lung cancer following treatment with EGFR tyrosine kinase inhibitors in a patient with lung adenocarcinoma.
    Watanabe S; Sone T; Matsui T; Yamamura K; Tani M; Okazaki A; Kurokawa K; Tambo Y; Takato H; Ohkura N; Waseda Y; Katayama N; Kasahara K
    Lung Cancer; 2013 Nov; 82(2):370-2. PubMed ID: 24012411
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapid increase of serum neuron specific enolase level and tachyphylaxis of EGFR-tyrosine kinase inhibitor indicate small cell lung cancer transformation from EGFR positive lung adenocarcinoma?
    Zhang Y; Li XY; Tang Y; Xu Y; Guo WH; Li YC; Liu XK; Huang CY; Wang YS; Wei YQ
    Lung Cancer; 2013 Aug; 81(2):302-5. PubMed ID: 23683536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinicopathological and genomic comparisons between different histologic components in combined small cell lung cancer and non-small cell lung cancer.
    Lin MW; Su KY; Su TJ; Chang CC; Lin JW; Lee YH; Yu SL; Chen JS; Hsieh MS
    Lung Cancer; 2018 Nov; 125():282-290. PubMed ID: 30429033
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gastric metastasis and transformation of primary lung adenocarcinoma to small cell cancer after acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors: A case report.
    Liu J; Xia L; Peng Y; Huang YS; Yang ZZ
    Medicine (Baltimore); 2021 Oct; 100(39):e27289. PubMed ID: 34596125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Small cell transformation of non-small cell lung cancer on immune checkpoint inhibitors: uncommon or under-recognized?
    Sehgal K; Varkaris A; Viray H; VanderLaan PA; Rangachari D; Costa DB
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581048
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic alterations and protein expression in combined small cell lung cancers and small cell lung cancers arising from lung adenocarcinomas after therapy with tyrosine kinase inhibitors.
    Shi X; Duan H; Liu X; Zhou L; Liang Z
    Oncotarget; 2016 Jun; 7(23):34240-9. PubMed ID: 27145273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hyperprogressive Disease in Lung Cancer with Transformation of Adenocarcinoma to Small-cell Carcinoma during Pembrolizumab Therapy.
    Okeya K; Kawagishi Y; Muranaka E; Izumida T; Tsuji H; Takeda S
    Intern Med; 2019 Nov; 58(22):3295-3298. PubMed ID: 31327828
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Case of ALK-Rearranged Adenocarcinoma with Small Cell Carcinoma-Like Transformation and Resistance to Crizotinib.
    Cha YJ; Cho BC; Kim HR; Lee HJ; Shim HS
    J Thorac Oncol; 2016 May; 11(5):e55-e58. PubMed ID: 26752677
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transformation to SCLC after Treatment with the ALK Inhibitor Alectinib.
    Fujita S; Masago K; Katakami N; Yatabe Y
    J Thorac Oncol; 2016 Jun; 11(6):e67-72. PubMed ID: 26751586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Small Cell Lung Cancer Transformation as a Mechanism of Resistance to PD-1 Therapy in KRAS-Mutant Lung Adenocarcinoma: A Report of Two Cases.
    Iams WT; Beckermann KE; Almodovar K; Hernandez J; Vnencak-Jones C; Lim LP; Raymond CK; Horn L; Lovly CM
    J Thorac Oncol; 2019 Mar; 14(3):e45-e48. PubMed ID: 30543839
    [No Abstract]   [Full Text] [Related]  

  • 16. Dual occurrence of ALK G1202R solvent front mutation and small cell lung cancer transformation as resistance mechanisms to second generation ALK inhibitors without prior exposure to crizotinib. Pitfall of solely relying on liquid re-biopsy?
    Ou SI; Lee TK; Young L; Fernandez-Rocha MY; Pavlick D; Schrock AB; Zhu VW; Milliken J; Ali SM; Gitlitz BJ
    Lung Cancer; 2017 Apr; 106():110-114. PubMed ID: 28285684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A case of resistance to tyrosine kinase inhibitor therapy: small cell carcinoma transformation concomitant with plasma-genotyped T790M positivity.
    Xu Y; Huang Z; Gong L; Fan Y
    Anticancer Drugs; 2017 Oct; 28(9):1056-1061. PubMed ID: 28723866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Case report: small cell transformation and metastasis to the breast in a patient with lung adenocarcinoma following maintenance treatment with epidermal growth factor receptor tyrosine kinase inhibitors.
    Lin Q; Cai GP; Yang KY; Yang L; Chen CS; Li YP
    BMC Cancer; 2016 Aug; 16():593. PubMed ID: 27488410
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-small cell lung cancer transdifferentiation into small cell lung cancer: A case series.
    Ahmed T; Vial MR; Ost D; Stewart J; Hasan MA; Grosu HB
    Lung Cancer; 2018 Aug; 122():220-223. PubMed ID: 30032836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Small cell lung cancer transformation and T790M mutation: complimentary roles in acquired resistance to kinase inhibitors in lung cancer.
    Suda K; Murakami I; Sakai K; Mizuuchi H; Shimizu S; Sato K; Tomizawa K; Tomida S; Yatabe Y; Nishio K; Mitsudomi T
    Sci Rep; 2015 Sep; 5():14447. PubMed ID: 26400668
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.